November 2020 PMID 32730705

Successful Response to Treatment with Sirolimus in Pulmonary Sarcoidosis.

Nishant Gupta, Jack H Bleesing, Francis X McCormack

Full text PDF Download social card

Mentions

Peak: 12 in Nov 2020

across 3 sources since Oct 2020

Extended reach

51,556

potential audience

Total likes

Video views

246

Mentions per month

Oct 2020 – Mar 2025

Where it's discussed

News46 articles
X / Twitter14 posts
YouTube2 videos

AI synopsis

What people are saying

The discussions indicate strong support for the publication's findings, with posts describing it as an 'interesting case report' and mentioning the potential of sirolimus as a targeted therapy. The tone varies from acknowledging the case's significance to curiosity about its broader applications, demonstrating both interest and a moderate level of engagement with the potential impact of this research.

AgreementModerate agreement

Most discussions acknowledge the positive outcome of using sirolimus for pulmonary sarcoidosis, reflecting general support for the findings.

InterestHigh interest

The topic appears highly relevant and intriguing, especially for medical professionals and researchers interested in novel treatments.

EngagementModerate engagement

Participants show moderate engagement by commenting on the case report and sharing related discussions, but do not deeply analyze the research details.

ImpactModerate impact

The discussions suggest a recognition that this publication could influence future therapeutic approaches, though the overall impact remains cautious pending further research.

Abstract in brief

The text discusses a case where a patient with pulmonary sarcoidosis, a lung condition characterized by inflammation and granuloma formation, was successfully treated using sirolimus, a medication typically used to prevent organ transplant rejection.
It highlights how sirolimus helped reduce inflammation and improve lung function, suggesting it could be an effective treatment option for sarcoidosis patients who do not respond to traditional therapies.
The report emphasizes the potential of sirolimus as a targeted therapy for pulmonary sarcoidosis, encouraging further research and clinical trials to confirm its safety and efficacy in broader patient populations.]

Read the full abstract

All mentions

Sirolimus Treatment for Cutaneous Sarcoidosis by mTOR Inhibition

Dr Anna Gabriel discusses her study on Sirolimus for treating skin sarcoidosis at Vienna's AKH University Clinic, highlighting how mTOR inhibition using Sirolimus shows promise for managing resistant sarcoidosis cases.

Lungenfibrose Forum Austria · Mar 21, 2025 125 views

Targeted mTOR Inhibition with Sirolimus for Pulmonary Sarcoidosis

Dr Anna Gabriel ne Redl discusses a sirolimus trial for sarcoidosis patients, highlighting its potential to reduce inflammation and improve lung function in cases unresponsive to traditional treatments.

Lungenfibrose Forum Austria · Mar 21, 2025 122 views

Fco. Javier Garcia Guillén

@Cometin007 · X